Randomized Controlled Clinical Trial to Evaluate The Efficacy and Safety of Healthtone as Prophylaxis for COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-03

Study Completion Date

2022-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background : Coronavirus disease known as COVID-19 is caused by the SARS-CoV-2. Transmission of SARS CoV-2 is spreading from human to human through direct or indirect droplets, this disease then spreads very quickly to various countries until it becomes a pandemic. Rhea® Health Tone is an essential oil made from Gardenia jasminoides, Commiphora myrrha, Boswellia serrata, Daucus carota, Foeniculum vulgarae, and Olea Europeae that have antimicrobial and anti-inflammatory effects. Rhea® Health Tone also has been registed on BPOM. Even so, the efficacy of Rhea® Health Tone still needs to be studied further.

This research aimed to assess the efficacy and safety of healthtone as prophylaxis for COVID-19 in human resources at persahabatan central general hospital.The intervention group received Rhea® Health Tone 2 times supplementation 1 ml a day; meanwhile, the control group received placebo 2 times supplementation 1 ml a day.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)

NCT05398965

COVID-19

COMPLETED PHASE2

Trial to Study the Efficacy and Safety of BEJO Red Ginger in COVID-19 Patients With Mild Symptoms

NCT05277155

COVID-19

UNKNOWN PHASE2/PHASE3

Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections

NCT01478009

Healthy Subjects

COMPLETED PHASE2/PHASE3

Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19

NCT05019326

Covid19

UNKNOWN PHASE3

Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient

NCT05936346

Aging

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a double-blind randomized clinical trial on the human resources population at Persahabatan Central General Hospital, Jakarta.

Subjects who have agreed to be included in the study will undergo an initial examination and a serological examination of IgG SARS-CoV-2 to ensure that there is no adequate immunity against COVID-19 before the study begins. After confirmed that all subjects are not included in the exclusion criteria and not infected with COVID-19, randomization will be conducted to determine who gets the Rhea®️ Health Tone or a placebo.

Evaluation will be carried out until the 84th day of giving the intervention. The subject will be monitored everyday by the research team to ask whether there are symptoms experienced by the subject, both symptoms related to COVID-19 and symptoms related to side effects drugs and adverse events.

The statistical test used in this study was the Chi-square test or Fisher's exact test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active (Investigational Product)

Investigational (Active) product:

Rhea® Health Tone (1.8 mg of Gardenia jasminoides; 1.8 mg Commiphora myrrha oil; 1.8 mg Boswellia serrata oil; 1.8 mg Daucus carota oil; 1.8 mg of Foeniculum vulgarae oil and 0.99 mg of Olea europeae oil or Olive oil as a solvent.)

Regimen:

Subjects will receive Rhea® Health Tone 2 times supplementation 1 ml a day for 84 days

Group Type EXPERIMENTAL

Rhea® Health Tone

Intervention Type DIETARY_SUPPLEMENT

Rhea® Health Tone

Placebo (Control Product)

Placebo (Control Product):

Using olive oil without the active ingredients contained in the Rhea® Health Tone test product.

Regimen:

Subjects will receive Placebo 2 times supplementation 1 ml a day for 84 days

Group Type PLACEBO_COMPARATOR

Rhea® Health Tone

Intervention Type DIETARY_SUPPLEMENT

Rhea® Health Tone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rhea® Health Tone

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-65 years old
* Human resources in persahabatan central general hospital while being a research subject
* Wear PPE according to their respective work standards.
* Not previously infected with COVID-19, or have been infected with COVID-19 19 previously with non-reactive IgG serological results.
* Have not received a COVID-19 vaccine or have received 2nd dose of vaccine COVID-19 but manifest non-reactive IgG serological results
* Subject voluntarily gave written consent to participate in this research.

Exclusion Criteria

* Patients with severe comorbid factors such as: uncontrolled congestive heart disease, renal insufficiency, coronary heart disease, chronic liver disease, diabetes mellitus with complications, uncontrolled hypertension or crisis hypertension, immunocompromised, CNS disorders (such as stroke, epilepsy, Alzheimer's, meningitis) , cancer, HIV, AIDS.
* Subjects who are pregnant or breastfeeding.
* Subjects who cannot be included in the study according to consideration of the researcher.
* Subjects who are in the process of taking other drug clinical trials.
* Subjects with a history of allergy to the components of the test drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes